Baicalin Attenuates Ketamine-Induced Neurotoxicity in the Developing Rats: Involvement of PI3K/Akt and CREB/BDNF/Bcl-2 Pathways
- 599 Downloads
Ketamine is widely used as an anesthetic in pediatric clinical practice. However, numerous studies have reported that exposure to ketamine during the developmental period induces neurotoxicity. Here we investigate the neuroprotective effects of baicalin, a natural flavonoid compound, against ketamine-induced apoptotic neurotoxicity in the cortex and hippocampus of the Sprague–Dawley postnatal day 7 (PND7) rat pups. Our results revealed that five continuous injections of ketamine (20 mg/kg) at 90-min intervals over 6 h induced obvious morphological damages of neuron by Nissl staining and apoptosis by TUNEL assays in the prefrontal cortex and hippocampus of PND7 rat pups. Baicalin (100 mg/kg) pretreatment alleviated ketamine-induced morphological change and apoptosis. Caspase-3 activity and caspase-3 mRNA expression increase induced by ketamine were also inhibited by baicalin treatment. LY294002, an inhibitor of PI3K, abrogated the effect of baicalin against ketamine-induced caspase-3 activity and caspase-3 mRNA expression increase. In addition, Western blot studies indicated that baicalin not only inhibited ketamine-induced p-Akt and p-GSK-3β decrease, but also relieved ketamine-induced p-CREB and BDNF expression decrease. Baicalin also attenuated ketamine-induced Bcl-2/Bax decrease and caspase-3 expression increase. Further in vitro experiments proved that baicalin mitigated ketamine-induced cell viability decrease in the MTT assay, morphological change by Rosenfeld’s staining, and caspase-3 expression increase by Western blot in the primary neuron–glia mixed cultures. LY294002 abrogated the protective effect of baicalin. These data demonstrate that baicalin exerts neuroprotective effect against ketamine-induced neuronal apoptosis by activating the PI3K/Akt and its downstream CREB/BDNF/Bcl-2 signaling pathways. Therefore, baicalin appears to be a promising agent in preventing or reversing ketamine’s apoptotic neurotoxicity at an early developmental stage.
KeywordsKetamine Baicalin Neurotoxicity PI3K/Akt CREB/BDNF/Bcl-2
This study was supported by grants from the Natural Science Foundation of China (81403023), the Program for Liaoning Excellent Talents in University (LJQ2015111), and the Scientific Research Foundation for Returned Scholars, Ministry of Education of China.
Compliance with Ethical standards
Conflict of Interest
The authors declare that there are no conflicts of interest.
- Cheng F, Lu Y, Zhong X, Song W, Wang X, Sun X, Qin J, Guo S, Wang Q (2013) Baicalin’s Therapeutic Time Window of Neuroprotection during Transient Focal Cerebral Ischemia and Its Antioxidative Effects In Vitro and In Vivo. Evid Based Complement Alternat Med 2013:120261PubMedPubMedCentralGoogle Scholar
- Lee B, Sur B, Shim I, Lee H, Hahm DH (2014a) Baicalin improves chronic corticosterone-induced learning and memory deficits via the enhancement of impaired hippocampal brain-derived neurotrophic factor and cAMP response element-binding protein expression in the rat. J Nat Med 68(1):132–143CrossRefPubMedGoogle Scholar
- Li CT, Zhang WP, Fang SH, Lu YB, Zhang LH, Qi LL, Huang XQ, Huang XJ, Wei EQ (2010) Baicalin attenuates oxygen-glucose deprivation-induced injury by inhibiting oxidative stress-mediated 5-lipoxygenase activation in PC12 cells. Acta Pharmacol Sin 31(2):137–144CrossRefPubMedPubMedCentralGoogle Scholar
- Michel PP, Hirsch EC, Agid Y (2002) Parkinson’s disease: cell death mechanisms. Rev Neurol (Paris) 158(122):24–32Google Scholar
- Parisi OI, Scrivano L, Sinicropi MS, Picci N, Puoci F (2015) Engineered polymer-based nanomaterials for diagnostic. Therapeutic Theranostic Appl, Mini Rev Med ChemGoogle Scholar
- Pitanga BP, Silva VD, Souza CS, Junqueira HA, Fragomeni BO, Nascimento RP, Silva AR, Costa Mde F, El-Bacha RS, Costa SL (2011) Assessment of neurotoxicity of monocrotaline, an alkaloid extracted from Crotalaria retusa in astrocyte/neuron co-culture system. Neurotoxicology 32(6):776–784CrossRefPubMedGoogle Scholar
- Scallet AC, Schmued LC, Slikker W Jr, Grunberg N, Faustino PJ, Davis H, Lester D, Pine PS, Sistare F, Hanig JP (2004) Developmental neurotoxicity of ketamine: morphometric confirmation, exposure parameters, and multiple fluorescent labeling of apoptotic neurons. Toxicol Sci 81(2):364–370CrossRefPubMedGoogle Scholar
- Sprung J, Flick RP, Katusic SK, Colligan RC, Barbaresi WJ, Bojanic K, Welch TL, Olson MD, Hanson AC, Schroeder DR, Wilder RT, Warner DO (2012) Attention-deficit/hyperactivity disorder after early exposure to procedures requiring general anesthesia. Mayo Clin Proc 87(2):120–129CrossRefPubMedPubMedCentralGoogle Scholar